Introduction
Daratumumab (Darzalex; Darzalex Faspro SC formulation) has fundamentally reshaped the treatment of multiple myeloma (MM) since its initial FDA approval in 2015. Across pivotal trials in newly diagnosed transplant-eligible (NDMM-TE), newly diagnosed transplant-ineligible (NDMM-TI), and relapsed/refractory (RRMM) settings, daratumumab consistently deepens response—raising MRD-negativity rates, prolonging progression-free survival (PFS), and in several settings improving overall survival (OS)—with a manageable but quantifiable increase in cytopenias and infections. The subcutaneous (SC) formulation substantially reduces infusion-related reactions (IRRs) and chair time without sacrificing efficacy. Operational considerations—blood bank interference, SPEP/IFE masking of M-protein, and infection prophylaxis—require systematic mitigation. Guideline bodies (NCCN, ESMO, EHA–EMN) have broadly embedded daratumumab into standard-of-care induction and maintenance regimens, and reimbursement coverage has recently expanded globally, including China's 2024 National Reimbursement Drug List. The competitive landscape is evolving, with isatuximab as the direct anti-CD38 competitor and BCMA/GPRC5D-directed therapies providing growing efficacy pressure in relapse settings.
1. Mechanism of Action and Product Modalities
Daratumumab is a human IgG1 kappa monoclonal antibody that binds CD38, a transmembrane glycoprotein highly expressed on malignant plasma cells 1. Its anti-tumor activity is mediated through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), collectively inducing direct tumor cell killing and immune-effector recruitment 3. A pharmacologically notable feature is that daratumumab persists in circulation for up to 70 days post-treatment, with implications for laboratory monitoring 1.
IV vs SC formulations: The SC formulation (Darzalex Faspro, 1,800 mg co-formulated with recombinant human hyaluronidase rHuPH20) was developed to improve convenience. The pivotal Phase 3 COLUMBA study established SC non-inferiority to IV daratumumab: the Ctrough ratio was 108%, ORR was 41% vs 37%, and PFS was comparable 1829. Most importantly, IRRs were markedly reduced (12.7% SC vs 34.5% IV), and administration time collapsed from 3.5–7 hours (first IV infusion) to approximately 3–5 minutes for SC injection 1829. A prospective time-and-motion survey across 16 international centers confirmed a 97% reduction in patient chair time per visit and a 50% annual reduction in active healthcare provider time. As of January 2026, Darzalex Faspro received a new FDA approval for use with VRd in transplant-ineligible NDMM, further broadening SC indications 1920.
2. Clinical Efficacy Across Settings
Newly Diagnosed, Transplant-Eligible (NDMM-TE)
| Trial | Regimen | Key Efficacy Outcome |
|---|---|---|
| CASSIOPEIA | D-VTd vs VTd | Median PFS 83.7 vs 52.8 mo (HR 0.61, p<0.0001); OS HR 0.55 (p<0.0001); sCR 28.9% vs 20.3%; MRD-neg 64% vs 44% post-consolidation 18 |
| PERSEUS | D-VRd vs VRd | 48-month PFS 84.3% vs 67.7% (HR 0.42, p<0.001); CR or better 87.9% vs 70.1%; MRD-neg 75.2% vs 47.5% 11 |
| GRIFFIN (Ph2) | D-RVd vs RVd | sCR 67% vs 48% (p=0.0079); MRD-neg 64.4% vs 30.1%; 48-month PFS 87.2% vs 70% (HR 0.45) 18 |
Daratumumab maintenance post-ASCT in CASSIOPEIA further improved 72-month PFS (57.1% vs 36.5%) 18, establishing maintenance as an evidence-supported strategy.
Newly Diagnosed, Transplant-Ineligible (NDMM-TI)
| Trial | Regimen | Key Efficacy Outcome |
|---|---|---|
| MAIA | D-Rd vs Rd | PFS 61.9 vs 34.4 mo (HR 0.55, p<0.0001); OS HR 0.66 (p=0.0003); median OS not reached vs 65.5 mo; ORR 92.9% vs 81.6%; MRD-neg 32.1% vs 11.1% 18 |
| ALCYONE | D-VMP vs VMP | OS 82.7 vs 53.6 mo (HR 0.63, p<0.0001); 72-month OS 55.8% vs 39.2%; MRD-neg 28.3% vs 7.0% 18 |
| CEPHEUS | D-VRd vs VRd (SC) | MRD-neg 52.3% vs 34.8%; PFS HR 0.60 (basis for January 2026 FDA approval) 1920 |
MAIA and ALCYONE both demonstrated OS benefit, cementing daratumumab as a standard-of-care anchor in elderly/transplant-ineligible patients.
Relapsed/Refractory MM (RRMM)
| Trial | Regimen | PFS HR | MRD-Negativity | ORR |
|---|---|---|---|---|
| POLLUX | D-Rd vs Rd | 0.37; median 44.5 vs 17.5 mo 2 | 30.4% vs 5.3% 2 | 92.9% vs 76.4% 2 |
| CASTOR | D-Vd vs Vd | 0.39; median NR vs 7.16 mo 18 | 10% vs 2% 18 | 83% vs 63% 18 |
| CANDOR | D-Kd vs Kd | 0.64; 28.4 vs 15.2 mo 18 | 28% vs 9% 18 | — |
| LEPUS (China) | D-Vd vs Vd | 0.35; 14.8 vs 6.3 mo 18 | — | 84.7% vs 66.7% 18 |
For monotherapy in heavily pretreated disease, SIRIUS reported an ORR of 29.2% and GEN501 an ORR of 36%, with rapid responses (median ~0.9 months) 18. Early M-protein dynamics within the first 2 months are predictive of long-term PFS (AUC ~0.8–0.85 in POLLUX/CASTOR models), enabling early prognostication 15.
3. Safety and Tolerability Profile
The safety profile is predictable and manageable, characterized by three principal concerns:
Infusion-Related Reactions (IRR): Predominantly first-infusion, mostly grade 1–2. IV daratumumab IRR rates range from 27–48% across trials (e.g., 27.7% in ALCYONE 7; 35.4% in CASSIOPEIA 18). SC daratumumab reduces this to 12.7% (COLUMBA) 1829.
Cytopenias and Infections: Adding daratumumab consistently increases grade 3/4 neutropenia and infections. Representative data:
| Setting | Grade 3/4 Neutropenia | Grade 3/4 Infections |
|---|---|---|
| MAIA (D-Rd vs Rd) | 54.1% vs 37.0% 18 | 42.6% vs 29.6% 18 |
| ALCYONE (D-VMP vs VMP) | 39.9% vs 38.7% 7 | 29.8% vs 15.0% 18 |
| PERSEUS (D-VRd vs VRd) | 62.1% vs 51.0% 11 | — |
Infection prophylaxis is essential: IMWG guidelines recommend antiviral prophylaxis (acyclovir) for VZV-seropositive patients, consideration of levofloxacin during high-risk periods, trimethoprim-sulfamethoxazole or dapsone for PJP prophylaxis in at-risk patients, and IVIG reserved for recurrent life-threatening infections. HBV reactivation monitoring is warranted.
No new safety signals have emerged with extended follow-up across major programs 18.
4. Operational and Diagnostic Considerations
Blood Bank Interference: Daratumumab binds CD38 on reagent RBCs, causing panagglutination in indirect antiglobulin tests (IAT). DTT (dithiothreitol) treatment of reagent RBCs effectively abrogates this interference. DTT-treated reagent red cells can substantially mitigate daratumumab-related interference in pretransfusion testing and may reduce turnaround time and resource use; however, the magnitude of benefit depends on local laboratory workflows. Current AABB and IMWG guidance recommends RBC phenotype or genotype determination before daratumumab initiation.
SPEP/IFE Interference: Daratumumab appears as an IgG kappa M-protein band on SPEP/IFE, potentially masking complete response assessment. A validated biotinylated recombinant CD38 capture technique using streptavidin-coated magnetic beads removes daratumumab selectively, with M-protein quantitation correlation R²=0.9984, requiring only 15 minutes and costing approximately 20% of alternative assays (DIRA/Hydrashift) 1.
Chair Time and Throughput: SC administration reduces patient chair time by 97% and annual healthcare provider time by 50% per patient compared to IV, translating to substantial clinic throughput gains and improved patient quality of life 17.
5. Patient Subgroup Performance and Sequencing
Elderly patients: Subgroup analyses from POLLUX and CASTOR in patients aged ≥75 years confirmed consistent benefit: PFS HR 0.27 (D-Rd) and 0.26 (D-Vd) versus backbone alone, with higher IRR rates (41–65%) but no new safety signals 10.
High-risk cytogenetics: CANDOR demonstrated PFS HR 0.52 in high-risk cytogenetic subgroups 18; LEPUS similarly showed maintained benefit in Chinese patients 18.
Renal impairment and special populations: Japanese and Chinese real-world cohorts confirmed manageable safety, with successful treatment of patients with HBV surface antigen positivity and dialysis dependence 513.
Sequencing considerations: Prior anti-CD38 exposure and refractoriness are now primary determinants of second-line selection. After daratumumab, BCMA-directed therapies (ide-cel, cilta-cel, teclistamab) represent logical next steps. Notably, the FDA approved teclistamab plus daratumumab/hyaluronidase-fihj in March 2026 for RRMM, positioning daratumumab as a combination backbone for next-generation immune therapies 2627. European Myeloma Network practical guidance addresses sequencing of BCMA- and GPRC5D-targeting agents 33, though detailed sequencing algorithms from full guideline texts were not accessible in the retrieved materials.
6. Health Economics and Guideline Positioning
Reimbursement landscape:
| Market | Status |
|---|---|
| USA | Multiple approved indications (IV + SC); NICE TA917 in UK |
| EU | ESMO and EHA-EMN guidelines support daratumumab-based induction 3435 |
| China | Included in 2024 NRDL (effective January 1, 2025); both IV and SC formulations; average NRDL price cut ~63% |
A cost-effectiveness analysis from the Iranian payer perspective found DRd superior to KRd at an ICUR of $956/QALY, with incremental cost of only $264—though daratumumab pricing remains the principal sensitivity driver.
Guideline positioning: NCCN Multiple Myeloma Version 5.2026 includes daratumumab-based regimens such as D-VRd among recommended options and discusses MRD assessment as an important disease-evaluation tool 30. ESMO and EHA-EMN guidelines broadly endorse anti-CD38-based induction for transplant-eligible and ineligible NDMM and key RRMM combinations 343536. Specific algorithmic details from full guideline texts were not fully accessible in the retrieved materials.
7. Competitive Landscape and Future Outlook
Comparison with Isatuximab
Daratumumab leads on breadth of label (including frontline SC expansion), while isatuximab competes in carfilzomib-based (Isa-Kd, median PFS ~42 months at 44-month follow-up) and pomalidomide-based RRMM settings 2329. No head-to-head trials exist; indirect comparisons are methodologically limited 2122.
Comparison with BCMA/GPRC5D-Targeted Therapies
Cilta-cel achieved ORR 97–98% and 5-year PFS 33% in RRMM 1824; ide-cel achieved ORR 73% in KarMMa-1 24. CAR-T provides higher peak efficacy in selected fit patients but is constrained by manufacturing lead time, center access, and immune toxicities. The strategic response from the daratumumab franchise is to migrate into combination roles—as illustrated by the teclistamab+daratumumab approval—preserving daratumumab's relevance as an immunotherapy backbone rather than merely a competitive target 2627.
Practical adoption framework:
| Setting | Preferred Daratumumab Role | Key Mitigation |
|---|---|---|
| NDMM-TE | D-VTd or D-VRd induction + ASCT + DARA maintenance | Monitor cytopenias; antiviral prophylaxis |
| NDMM-TI | D-Rd (MAIA) or D-VMP (ALCYONE) or D-VRd (CEPHEUS) | SC preferred to reduce IRR/chair time |
| RRMM 1st–3rd line | D-Rd, D-Vd, D-Kd; consider SC to improve throughput | Blood bank pre-testing; SPEP/IFE monitoring |
| Early relapsed/refractory MM after at least one prior line of therapy | Teclistamab plus daratumumab may be considered where approved and appropriate | Infection management remains critical |
| Elderly/frail | Consistent benefit confirmed ≥75 years; dose/backbone modification per comorbidities | Infection monitoring; dose flexibility |
In sum, daratumumab has a favorable benefit–risk profile across approved multiple myeloma settings, although treatment selection should still be individualized according to disease setting, prior exposure, comorbidity burden, and infection risk. The SC formulation substantially mitigates the principal operational burden of IV administration, making widespread outpatient adoption practical. Systematic attention to blood bank preparation, SPEP/IFE interference management, and infection prophylaxis converts the residual safety risks into manageable clinical workflows. As the myeloma therapeutic landscape evolves toward BCMA/GPRC5D-directed cellular and bispecific therapies, daratumumab is transitioning from a standalone backbone to a foundational partner in next-generation immune combinations—a strategic position that is likely to sustain an important role in myeloma management through the foreseeable future 12192627.